----
Current ValuationThe current P/E ratio is -0.69, above the reasonable range, cheaper than 6.51% of the time in the past 1 years, and the industry ranks 174/605, the industry Median -1.93.
-0.687xP/E
$0.21Stock price
$-0.31Earnings per share
-0.687xP/E
Stock price$0.21Earnings per share$-0.31
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.61x
- Typical range
- -2.19x–-0.99x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -59.90x | 150.48% | $194.07B |
MRNAUSModerna | -30.67x | 15.63% | $96.65B |
CSLLYUSCSL Limited | -25.62x | -- | $66.07B |
NTRAUSNatera | -304.20x | 6.85% | $58.51B |
RVMDUSRevolution Medicines | -23.82x | 61.83% | $42.13B |
ROIVUSRoivant Sciences | -94.74x | 146.49% | $25.22B |
BNTXUSBioNTech SE | -11.72x | 19.35% | $22.90B |
INSMUSInsmed | -23.87x | 75.01% | $20.89B |
BBIOUSBridgebio Pharma | -19.09x | 28.60% | $13.21B |
SMMTUSSummit Therapeutics | -14.99x | 20.65% | $12.84B |
MDGLUSMadrigal Pharma | -33.23x | 51.30% | $10.80B |
PCVXUSVaxcyte | -9.79x | 47.91% | $10.42B |
KYMRUSKymera Therapeutics | -31.49x | 5.24% | $9.43B |
TWSTUSTwist Bioscience | -68.71x | 28.71% | $9.39B |
IBRXUSImmunityBio | -9.37x | 151.32% | $9.29B |
CYTKUSCytokinetics | -9.94x | 6.85% | $8.89B |
ARWRUSArrowHead Pharma | -26.01x | 35,923.70% | $8.32B |
ABVXUSAbivax SA | -17.36x | 22.99% | $8.07B |
SYREUSSpyre Therapeutics | -53.65x | 45.60% | $8.06B |
IONSUSIonis Pharma | -13.35x | 51.03% | $7.54B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
